Mars Petcare Marks Strategic Entry into European Veterinary Care Sector as Anicura to Join the Business
Mars Petcare today announced that it has signed definitive agreements to acquire AniCura from Nordic Capital, Fidelio Capital and the remaining minority shareholders of AniCura. On completion of the transaction, AniCura will join the family of Mars Petcare’s veterinary health business units and will continue to pursue the expansion of its brand and high quality standards of medicine in Europe.
AniCura was founded in 2011 as the first merger of animal hospitals in the Nordic region. Since then, it has grown to become a role model for high-quality, specialized veterinary care for companion animals. AniCura now has more than 4,000 veterinary professionals, and 200 animal hospitals in seven countries across Europe. Its vision is to provide a first-class customer experience for pet owners and referring veterinarians alike.
The acquisition of AniCura represents Mars Petcare’s strategic entry into the European veterinary care sector. It brings together Mars Petcare’s notable veterinary expertise with AniCura’s well-established European business. This follows the announcement earlier in June 2018 that Linnaeus – a high-quality provider of veterinary care based in the UK – will also join Mars Petcare and will become a unit within Mars Petcare’s Veterinary Health Group.
Mars Petcare has been providing veterinary care since 1994 when it first began partnering with BANFIELD™ Pet Hospital. Today, it employs approximately 50,000 veterinary professionals and cares for more than 10 million pets annually. AniCura will join the family of Mars Petcare’s veterinary businesses alongside VCA™, BANFIELD™ Pet Hospital, BLUEPEARL™, PET PARTNERS™ and Linnaeus. Mars Petcare’s purpose is to create A BETTER WORLD FOR PETS and it is building upon and leveraging capabilities across its pet businesses to bring this to life. This includes food & nutrition, research, technology, and veterinary expertise – from wellness and prevention, through all aspects of veterinary care.
“Mars Petcare has a long and global history of providing nutrition, veterinary care and science for pets across the globe. Our veterinary business until now has been in the United States and Canada. Europe is the second largest region in the world for pet care, and European pet care is expected to grow significantly over the coming years. There is a great opportunity to address growing demand by providing high quality, consistent veterinary care across Europe”, said Poul Weihrauch, President, Mars Petcare. “Together, Mars Petcare and AniCura will both be in a position to benefit from each other’s best practices and competencies, improving clinical practice and continuing to advance the veterinary profession in both North America and Europe. This will support us in our purpose to create A BETTER WORLD FOR PETS.”
AniCura is well renowned for practicing quality medicine across its 200 animal hospitals and for the two million pets it cares for every year. It has well-regarded specialist care focus and a highly-qualified team, employing a high share of Diplomates from the European College across Sweden, Norway, Denmark, Germany, Austria, Switzerland and The Netherlands.
“Over the past years, with support from Nordic Capital and the additional owners, AniCura has grown to become a leading European provider of high-quality veterinary care, well-known for its focus on people, customer care and quality. The company is now ready to take the next step in its development”, said Peter Dahlberg, Chief Executive Officer, AniCura. “It was clear from early on that Mars Petcare shared our values of providing high-quality veterinary care and a first-class customer experience, and we are pleased to have found a long-term owner for AniCura to further improve the quality of European veterinary care”.
Completion of the transaction is subject to customary regulatory approvals. It is expected that the transaction will close in Q4 2018.
On completion of the deal, AniCura’s existing management will continue to lead the business. As part of the Mars Petcare family, AniCura will continue with the expansion of its brand and high quality standards of medicine in Europe. Financial terms of the transaction were not disclosed.
J.P. Morgan Securities plc acted as financial adviser and Freshfields Bruckhaus Deringer LLP and Cederquist acted as legal counsel to Mars.
About Mars Petcare
Mars Petcare is a diverse and growing business with 75,000 Associates across 50+ countries dedicated to one purpose: A BETTER WORLD FOR PETS. With 75 years of experience, our portfolio of almost 50 brands serves the health and nutrition needs of the world’s pets – including brands PEDIGREE ®, WHISKAS ®, ROYAL CANIN®, NUTRO™, GREENIES™, SHEBA ®, CESAR ®, IAMS™ and EUKANUBA™ as well as The WALTHAM Centre for Pet Nutrition which has advanced research in the nutrition and health of pets for over 50 years. Mars Petcare is also a leading veterinary health provider through a network of over 2,000 pet hospitals including BANFIELD™, BLUEPEARL™, PET PARTNERS™, and VCA™. We’re also active in innovation and technology for pets, with WISDOM PANEL™ genetic health screening and DNA testing for dogs, the WHISTLE™ GPS dog tracker, and LEAP VENTURE STUDIO accelerator and COMPANION FUND™ programs that drive innovation and disruption in the pet care industry. As a family business and guided by our principles, we are privileged with the flexibility to fight for what we believe in – and we choose to fight for: A BETTER WORLD FOR PETS.
AniCura is a family of well-known animal hospitals and clinics specialised in veterinary care for companion animals. Born out of the idea that sharing resources creates opportunities for better veterinary care, the company was established in 2011 by Fidelio Capital and The Animal Foundation in Greater Stockholm as the first merger of companion animal hospitals in the Nordic region. Today, AniCura is a role model within specialised veterinary care and a valued partner for pet owners and referring veterinarians across Europe. AniCura offers a wide range of high quality medical services covering preventive and basic health care as well as advanced diagnostics, internal medicine, intensive care, surgery and orthopaedics. AniCura also provides rehabilitation, physiotherapy and dietary advice and offers selected pet food and care products. AniCura provides modern, high-quality veterinary care for pets at 200 European locations and creates peace of mind for pet owners through excellent access and patient safety. Every year, AniCura’s 4,000 passionate veterinary professionals attend to more than two million companion animal patients. AniCura is a trusted training and referral body. For information on how AniCura is working to shape the future of veterinary care, please visit our website www.anicuragroup.com.
About Nordic Capital
Nordic Capital is a leading private equity investor in the Nordic region with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a proven track record. Core sectors are Healthcare, Technology & Payments, Financial Services, Industrial Goods & Services and Consumer & Retail, and key regions are the Nordics, Northern Europe, and globally for Healthcare. Since inception in 1989, Nordic Capital has invested EUR 12 billion in 100 investments. The Nordic Capital Funds are based in Jersey and are advised by advisory entities, which are based in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital, please visit www.nordiccapital.com.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI for Pivotal Study Patients18.6.2019 10:00:00 CEST | Pressemelding
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration (“FDA”) approved the use of full-body magnetic resonance imaging (“MRI”) using 1.5 Tesla MRI scanners for clinical study patients implanted with the Axonics System. The approval was a result of a supplement filed by Axonics with the FDA under the Investigational Device Exemption (“IDE”) regarding the Company’s ARTISAN-SNM 129-patient pivotal clinical study. The FDA concluded that Axonics provided sufficient data to support full-body MRIs. Raymond W. Cohen, CEO of Axonics, commented, “Allowing full-body MRI scans for our clinical study patients means that none will have to undergo an explant of their neurostimulator device should they require an MRI. We view this as a very positive step by the FD
Norsk Titanium Receives Airbus Contract for Qualification and Production18.6.2019 10:00:00 CEST | Pressemelding
Officials with Norsk Titanium (Norsk) announce today a contract award from Airbus for the Qualification and Serial Production of the first parts to be manufactured utilizing wire-based Direct Energy Deposition (DED) additive manufacturing technology. “We have worked closely with Airbus over several years to demonstrate the technological maturity and the industrial readiness of our Rapid Plasma Deposition™ (RPD™) process,” said Norsk President and CEO Michael Canario. “This contract award is structured to enable long-term, serial production immediately following qualification. Our Plattsburgh, New York facility, with the assistance of Airbus technical leadership, has been preparing for this moment and is eager to demonstrate a 21st century advanced additive manufacturing capability.” This qualification of Airbus parts will demonstrate the suitability of the DED additive manufacturing process for aircraft structural parts. It will formalize the process by which individual parts are produ
Innovusion Announces Its High-Resolution Image-Grade LiDAR System “Cheetah”, Enabling the Safest Performance in the Vehicle Mobility Industry18.6.2019 09:00:00 CEST | Pressemelding
Innovusion Inc., the worldwide leader in the design and development of innovative hybrid Solid State LiDAR systems for vehicle safety applications, has announced the availability of its Cheetah system. Based on its innovative rotating polygon optical architecture, Innovusion has melded together proprietary detector electronics, advanced optics and sophisticated software algorithms to offer a system that has no equal in the long-distance, high-resolution LiDAR vehicle mobility system industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190618005066/en/ Innovusion's Cheetah long-distance LiDAR System...the safest in the mobility safety industry (Graphic: Business Wire) Smart architecture, streamlined optics design, and integrated optical paths result in rapid manufacturing, scalability into automotive production, and lower cost. The ability to provide a detection range of 200 meters on objects with 10% reflectivity and cle
You Bank the Digital Asset Banking Platform Presents at UNCHAIN 2019 in Berlin18.6.2019 08:25:00 CEST | Pressemelding
The Blockchain Conference UNCHAIN 2019 was held in Berlin, Germany, from June 14 to 15, 2019. You Bank, a digital asset banking platform, attended and delivered a speech at the conference. You Bank has henceforth made a brilliant appearance in the European market and officially opened the prelude of the global layout! You Bank’s Digital Asset Banking Platform, the Federal Reserve of the Digital World You Bank, a world-class multinational blockchain financial service platform, is a well-deserved global leader in the field of digital asset management. Headquartered in Singapore, You Bank was founded by the Richmond family, one of the nine Jewish families known as the "Rothschild" family in the digital world. You Bank Global CEO Daniel attended and delivered a speech at the conference. He introduced that the original intention of You Bank was to establish a digital bank which could operate world-widely in the digital economy era. You Bank will cover digital asset management, digital asset
Temenos Successfully Delivers a Single, State-of-the-Art Digital Platform for ABN AMRO’s Private and Corporate Banking Business18.6.2019 08:00:00 CEST | Pressemelding
Temenos (SIX: TEMN), the banking software company, today announced that ABN AMRO has gone live with Temenos’ WealthSuite digital banking platform, which will power the bank’s international operations for private and corporate banking. The shift to a single shared digital banking platform will allow ABN AMRO to reduce IT operational costs and achieve an improved cost/ income ratio. The open digital banking platform will future-proof ABN AMRO’s growth and enable the bank to deliver innovative and personalized products and services faster to market. Belgium is the first international branch to go live with the Temenos solution under ABN AMRO’s rollout plan, which will see the bank migrate two additional countries on the new platform in the coming years. ABN AMRO joins the growing list of top tier banks that have deployed Temenos WealthSuite to transform their wealth management operations. With Temenos WealthSuite, ABN AMRO will deploy an end-to-end, highly scalable and configurable platfo
Hansol Paper and Iconex Announce Mutual Decision to Withdraw from Agreement Governing Sale of Schades and R+S to Iconex18.6.2019 08:00:00 CEST | Pressemelding
Iconex and Hansol Paper announced today that the companies are withdrawing from their definitive agreement signed November 2, 2018, under which Iconex would have acquired Schades and R+S from Hansol Paper. This decision, reached by mutual agreement between the parties, is due to the ruling of The United Kingdom’s Competition and Markets Authority (CMA) to move the approval process for this transaction to Phase 2. This allows the UK CMA an additional six months to reach a decision, which was deemed to be too long of a delay by both parties. The parties believe that the proposed transaction met the relevant legal criteria for approval in the UK, and that it was in the best interests of our customers, employees and the marketplace in the United Kingdom and beyond. This UK CMA decision was unexpected by both parties given that the European Commission cleared the deal earlier this spring. Like elsewhere in Europe, the UK market is highly competitive with a significant number of players. “Th